+

US20020110596A1 - Pharmaceutical compositions for the controlled release of active substances - Google Patents

Pharmaceutical compositions for the controlled release of active substances Download PDF

Info

Publication number
US20020110596A1
US20020110596A1 US10/055,962 US5596202A US2002110596A1 US 20020110596 A1 US20020110596 A1 US 20020110596A1 US 5596202 A US5596202 A US 5596202A US 2002110596 A1 US2002110596 A1 US 2002110596A1
Authority
US
United States
Prior art keywords
release
active substance
matrices
tablets
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/055,962
Inventor
Domenico Fanara
Monique Berwaer
Ann Bouquelle
Michel Deleers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/055,962 priority Critical patent/US20020110596A1/en
Publication of US20020110596A1 publication Critical patent/US20020110596A1/en
Priority to US10/607,047 priority patent/US7083807B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to pharmaceutical compositions which can be administered orally, allowing the controlled release of pharmaceutically active substances, and to methods of preparing these pharmaceutical compositions.
  • compositions which can be administered orally are to control the release of pharmaceutically active substances so that they can be administered in a few daily doses, ideally in a single daily dose.
  • the release of active substances during oral administration can be controlled by means of matrix-type pharmaceutical compositions.
  • matrix-type pharmaceutical compositions Depending on the excipients used, it is possible to identify three types of matrix: inert, hydrophilic and lipophilic matrices. Mixed matrices can also be created by combining excipients for these various types of matrix.
  • the inert matrices comprise excipients essentially belonging to the class of thermoplastic polymers. They are inert towards biological tissues, other excipients in the formulation and the active substance. They are insoluble and indigestible in the fluids of the gastrointestinal tract.
  • excipients essentially belonging to the class of thermoplastic polymers. They are inert towards biological tissues, other excipients in the formulation and the active substance. They are insoluble and indigestible in the fluids of the gastrointestinal tract.
  • polyvinyl chloride polyethylene, vinyl acetate/vinyl chloride copolymers, polymethylmethacrylates, polyamides, silicones, ethyl cellulose, polystyrene and the like. They generally use a concentration ranging from 20 to 95%.
  • the hydrophilic matrices comprise gelling excipients which can be divided into three classes: the cellulose derivatives (hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methylcellulose and the like), the noncellulose polysaccharides (galactomannans, guar gum, carob gum, gum arabic, sterculia gum, agar, alginates and the like) and the acrylic acid polymers (carbopols 934P and 974P and the like). They are generally used at a concentration of 20 to 70%.
  • the lipid matrices comprise four types of fatty excipients: glycerides (mono-, di- or triglycerides: stearin, palmitin, laurin, myristin, hydrogenated castor or cottonseed oils, precirol and the like), fatty acids and alcohols (stearic, palmitic or lauric acids; stearyl, cetyl or cetostearyl alcohols, and the like), fatty acid esters (monostearates of propylene glycol and of sucrose, sucrose distearate and the like) and waxes (white wax, cachalot wax and the like). They are generally used at a concentration of 10 to 50%.
  • matrix-type excipients in pharmaceutical compositions makes it possible, in a number of cases, to slow down the release of the active substances by entrapment.
  • these matrix-type excipients do not always make it possible to sufficiently slow down the release of the active substance or to obtain the desired ideal release profiles.
  • the matrix-type pharmaceutical composition contains a substance which must imperatively be released in the stomach
  • the release of the active substance over sufficiently long periods depends not only on the type of excipients used in the composition, but also on the residence time of the pharmaceutical composition in the stomach. Accordingly, several documents mention the use of floating matrix tablets.
  • patent EP 205336 describes pharmaceutical compositions for the controlled release of active substances comprising a mixed matrix obtained from a mixture of ethers of cellulose and of a polyacrylic acid, of one of its derivatives or of their pharmaceutically acceptable salts, and comprising, in addition, from 10 to 50% by weight, relative to the total weight of matrix excipients, of effervescent foaming agent.
  • the effervescent foaming agent makes it possible to cause the pharmaceutical composition to float in the gastric fluid, thereby increasing the residence time in the stomach.
  • the effervescent foaming agent is an alkali or alkaine-earth metal bicarbonate which is preferably used in combination with an organic acid.
  • the floating in the gastric fluid does not allow other problems observed in the context of the control of the release of active substances from the matrix pharmaceutical compositions to be resolved.
  • the release of some active substances greatly depends on the pH. For example, some active substances are not at all released in the stomach, but in other areas of the gastrointestinal tract. In addition, for the same area of the gastrointestinal tract, the release profile will be different depending on whether or not the composition is administered together with a meal. For the active substances whose release depends on the ambient pH, it is therefore desirable to find novel matrix compositions which make it possible to regulate the rate of release so that the active substance can be released at the same rate regardless of the pH of the medium.
  • orally administrable solid pharmaceutical compositions combining, in a single unit, a portion exhibiting immediate release and a portion exhibiting delayed release have been described.
  • these compositions require methods of preparation which are technically very sophisticated and/or do not allow the desired release profiles to be obtained for all the active substances.
  • compositions according to the present invention do not require excessive quantities of matrix excipients and allow regular and continuous release of active substances over periods of at least 12 hours.
  • the present invention therefore relates to pharmaceutical compositions which can be administered orally, allowing the controlled release of at least one active substance, comprising
  • at least one alkalinizing agent soluble in an aqueous phase under physiological pH conditions selected from alkali or alkaline-earth metal hydroxides, carbonates, bicarbonates and phosphates, sodium borate as well as the basic salts of organic acids.
  • FIGS. 1 to 5 The present invention is in particular illustrated by FIGS. 1 to 5 :
  • FIG. 1 pseudoephedrine bioavailability profiles obtained with cetirizine (immediate release)/pseudoephedrine (controlled release) bilayer tablets;
  • FIG. 2 kinetics of in vitro release of trapidil; matrix tablets without alkalinizing agent:
  • FIG. 3 kinetics of in vitro release of trapidil; matrix tablets with alkalinizing agent;
  • FIG. 4 kinetics of in vitro release of hydrocodones; matrix tablets with and without alkalinizing agent;
  • FIG. 5 profiles of bioavailability of trapidil obtained with coated matrix tablets.
  • compositions according to the present invention comprise matrix excipients chosen from inert, hydrophilic and lipophilic matrices.
  • inert matrices which can be used according to the present invention are: polyvinyl chloride, polyethylene, vinyl acetate/vinyl chloride copolymers, polymethylmethacrylates, polyamides, silicones, ethyl cellulose, polystyrene and the like.
  • hydrophilic matrices which can be used according to the present invention are: cellulose derivatives (hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methylcellulose and the like), noncellulose polysaccharides (galactomannans, guar gum, carob gum, gum arabic, sterculia gum, agar, alginates and the like) and acrylic acid polymers (carbopols 934P and 974P and the like).
  • the hydrophilic matrices preferably used according to the present invention are hydroxypropyl celluloses, such as METHOCEL K or E.
  • the content of hydroxypropyl methylcellulose-type excipients in the compositions according to the present invention is preferably between 5 and 60% by weight relative to the total weight of the composition.
  • lipid matrices which can be used according to the present invention are: glycerides (mono-, di- or triglycerides: stearin, palmitin, laurin, myristin, hydrogenated castor or cottonseed oils, precirol and the like), fatty acids and alcohols (stearic acid, palmitic acid, lauric acid; stearyl alcohol, cetyl alcohol, cetostearyl alcohols, and the like), fatty acid esters (monostearates of propylene glycol and of sucrose, sucrose distearate and the like) and waxes (white wax, cachalot wax and the like).
  • glycerides mono-, di- or triglycerides: stearin, palmitin, laurin, myristin, hydrogenated castor or cottonseed oils, precirol and the like
  • fatty acids and alcohols stearic acid, palmitic acid, lauric acid
  • the matrix excipients may also be in the form of a mixture.
  • the pharmaceutical compositions of the invention do not comprise mixtures comprising a polyacrylic acid and at least one hydrophilic matrix of the cellulose type.
  • the alkalinizing agent which can be used according to the present invention should be soluble in the aqueous phase under physiological pH conditions so as to produce the desired effect.
  • the alkalinizing agent may be chosen from alkali or alkaline-earth metal hydroxides, carbonates, bicarbonates and phosphates, sodium borate as well as basic salts of organic acids (example: sodium citrate).
  • salts not soluble in water under physiological pH conditions such as magnesium stearate or dibasic calcium phosphate, are not suitable according to the present invention.
  • the quantity of alkalinizing agent present in the pharmaceutical compositions according to the present invention is ideally from 5 to 50% by weight relative to the total weight of the composition.
  • compositions according to the present invention may be of a wide variety of types.
  • vasoconstrictors may be chosen from vasoconstrictors, antihistamines, analgesics, antitussives and the like.
  • the applicant has in particular observed that the invention is particularly suited to active substances whose free base is less soluble in water than its pharmaceutically acceptable salts.
  • active substances are pseudoephedrine, ephedrine, phenylephrine, phenylpropanolamine, trapidil, hydrocodone, cetirizine, efletirizine, hydroxyzine, meclozine, buclizine, pentoxyverine, codeine, morphine, their optical isomers or their pharmaceutically acceptable salts.
  • the pharmaceutical compositions according to the present invention may also contain other excipients such as diluents (example: emcompress, lactose and the like), binders (avicel, starches, polyvinylpyrrolidone and the like), disintegrants (starches and modified starches, cellulose derivatives, alginic derivatives, pectins and the like), lubricants (talc, magnesium stearate, colloidal silica and the like), taste-masking agents ( ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodexin and their alkylated derivatives), flavourings or colourings as well as coaling agents (example: cellulose derivatives, methacrylic resins, polyvinyl chloride, nylons and the like).
  • diluents example: emcompress, lactose and the like
  • binders avicel, starches, polyvinylpyrrolidone and
  • the pharmaceutical composition is according to the present invention are generally provided in a solid form. It is important to underline that the beneficial effects of the invention are observed regardless of the presentation of the galenic form.
  • the pharmaceutical compositions according to the present invention are provided in the form of tablets, granules, microgranules and the like, these forms being coated or otherwise.
  • controlled-release pharmaceutical compositions according to the present invention can be prepared by various conventional methods known to persons skilled in the art.
  • compositions according to the present invention are prepared by a process comprising the following successive steps:
  • step ii tabletting of the homogeneous mixture obtained in step i, optionally after granulation.
  • the tabletting may be of various types and is ideally carried out by direct tabletting.
  • the optional granulation in step ii may be carried out either by the wet route or by the dry route, or alternatively by melt-granulation.
  • the controlled-release pharmaceutical compositions according to the invention are used in combination with one or more pharmaceutical compositions allowing immediate release of active substances.
  • these two types of compositions are present in the same unit, this makes it possible to obtain, in a single administration, both the immediate release of a first active substance and the prolonged release of the same or of a second active substance.
  • compositions which can be administered orally, comprising
  • the excipients allowing immediate release of the active substance may be chosen from diluents (encompress, lactose and the like), binders (Avicel, starches, polyvinylpyrrolidone and the like), disintegrants (starches and modified starches, cellulose derivatives, alginic derivatives, pectins and the like), lubricants (talc, magnesium stearate, colloidal silica and the like), taste-masking agents ( ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin and their alkylated derivatives), flavourings or colourings.
  • diluents encompress, lactose and the like
  • binders Avicel, starches, polyvinylpyrrolidone and the like
  • disintegrants starches and modified starches, cellulose derivatives, alginic derivatives, pectins and the like
  • lubricants talc, magnesium
  • compositions can be prepared according to various methods known to persons skilled in the art.
  • these combined pharmaceutical compositions may be provided in the form of a tablet in which at least one layer A is stuck to at least one layer B.
  • such pharmaceutical compositions may be prepared by a process comprising the following successive steps:
  • the tabletting step 2) may be preceded by a step of granulating the homogeneous mixtures obtained in step 1).
  • the multilayer tabletting machines which make it possible to prepare this type of tablet are Courtoy, Manesty, Hata, Fette, Killian type multilayer tabletting machines and the like.
  • the multilayer tablets are particularly well suited to cases of combinations of active substances for which very specific beneficial therapeutic effects have recently been obtained, for example, pseudoephedrine/cetirizine, hydrocodone/acetaminophen, immediate release hydrocodone/prolonged release hydrocodone.
  • Controlled-release pseudoephedrine tablets A, B and C containing 120 mg doses were prepared by direct tabletting from homogeneous mixtures having, respectively, the compositions presented in Table 1.
  • the A tablets contain 16% of matrix excipient and 14.25% of alkalinizing agent. They have a mean weight of 281.03 mg and a hardness of 104 N.
  • the B and C tablets for their part, contain no alkalinizing agent and contain 40% and 50% of matrix excipient respectively. They have a mean weight of 298.3 mg and 402.25 mg respectively, and their respective degrees of hardness are 118 N and 137 N. TABLE 1 Composition of the A, B and C tablets mg/tablet Constituents A B C Pseudoephedrine.HCl 120 120 120 Methocel K15M CR 45 120 — Methocel K100M CR — — 200 Na 2 CO 3 , anhydrous 40 — — Avicel pH 102 70.8 55.5 74 Aerosil 200 1.4 1.5 2 Magnesium stearate 2.8 3 4
  • the A, B and C tablets were also the subject of a test of bioavailability in man over a period of 32 hours.
  • the profiles of bioavailability obtained with the A, B and C tablets were compared with the bioavailability profile obtained by administering immediate release gelatin capsules of pseudoephedrine containing 60 mg doses, administered after an interval of 6 hours.
  • matrix tablets 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24 and 32 hours;
  • gelatin capsules 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 16, 24 and 32 hours.
  • pseudoephedrine levels were determined by a validated HPLC method (UV detection).
  • the active substance is released in a comparable manner for the A, B and C tablets.
  • This example illustrates the fact that, to obtain an adequate prolonged release of the active substance, a much smaller quantity of matrix excipient (16% instead of 40% or 50%) is sufficient when this excipient is combined with an alkalinizing agent.
  • Controlled-release pseudoephedrine tablets containing 120 mg doses and containing 15.4% of Methocel K15M CR and 13.7% of sodium carbonate were prepared by direct tabletting from a homogeneous mixture having the composition presented in Table 4 (D tablets). TABLE 4 D Tablets. Constituents mg/tablet Pseudoephedrine.HCl 120 Methocel K15M CR 45 Na 2 CO 3 , anhydrous 40 Avicel pH 102 82.5 Aerosil 200 1.4 Magnesium stearate 2.8
  • the D tablets have a mean weight of 292.5 mg. A portion of these tablets was coated with Opadry OY-B-28920 (polyvinyl alcohol, lecithin, xanthan gum, titanium dioxide, talc). The kinetics of in vitro release of pseudoephedrine from the coated or uncoated D tablets was determined in the same manner as in Example 1. The results are presented in Table 5. TABLE 5 Percentage release of pseudoephedrine. Time (h) Uncoated Coated 0 0 0 1 33.7 30.4 2 47.5 45.6 3 57.9 56.5 4 65.8 65.7 5 71.9 72.0 6 77.1 76.8 7 80.7 80.2 83.4 83.1
  • Controlled-release pseudoephedrine tablets containing 180 mg doses and containing 30% of Methocel K15M CR and 30% of sodium carbonate (E), sodium bicarbonate (F) or potassium hydrogen phosphate (G) were prepared by direct tabletting from homogeneous mixtures having the compositions presented in Table 6. TABLE 6 E, F and G tablets. mg/tablet Constituents E F G Pseudoephedrine.HC1 180 180 180 Methocel K15M CR 180 180 180 Na 2 CO 3 , anhydrous 180 — — NaHCO 3 — 180 — K 2 HPO 4 — — 180 Avicel pH 102 51 51 51 Aerosil 200 3 3 3 3 Magnesium stearate 6 6 6 6
  • Double-layer tablets containing 120 mg doses of controlled-release pseudoephedrine and 5 mg of immediate-release cetirizine were prepared in the following manner (H tablets).
  • the prolonged-release layer contains 16.1% of matrix excipient and 14.3% of sodium carbonate.
  • TABLE 8 Mixture H A Constituents mg/tablet Cetirizine.2HC1 5 Tablettose 41.3 Avicel pH 102 22.65 Aerosil 200 0.35 Magnesium stearate 0.7
  • Controlled-release trapidil tablets I and J containing 300 mg doses were prepared by direct tabletting from homogeneous mixtures having the compositions collated in Table 11.
  • the I and J tablets contain 33.3% of matrix excipient; the I tablets contain no alkalinizing agent and the J tablets contain 12.5% of alkalinizing agent. TABLE 11 Compositions of the I and J tablets. mg/tablet Constituents I J Trapidil 300 300 Methocel K100M CR 200 200 Na 2 CO 3 , anhydrous — 75 Avicel pH 102 91 16 Aerosil 200 3 3 Magnesium stearate 6 6
  • the mean weights and the degrees of hardness of the I and J tablets are 605.3 mg and 125 N (I) and 597.7 mg and 79 N (J), respectively.
  • the kinetics of in vitro release of trapidil were determined according to the method described in Example 1 using two dissolution media: a 0.1 N solution of hydrochloric acid and a solution of phosphate buffer at pH 7.5. The speed of rotation of the baskets was 100 rpm. The results of this study are presented in Table 12, as well as in FIGS. 2 and 3.
  • FIG. 2 and the results presented in Table 12 for the I tablets show that these tablets exhibit very different release kinetics depending on the pH. These results show that a controlled and prolonged release cannot be obtained in a strongly acidic medium when there is no alkalinizing agent in the pharmaceutical composition.
  • FIG. 3 and the results presented in Table 12 for the J tablets show that a prolonged release of the active substance may very well be obtained in a strongly acidic medium when an alkalinizing agent Is present in the pharmaceutical composition.
  • Controlled-release hydrocodone tablets K and L containing 15 mg doses were prepared by direct tabletting from homogeneous mixtures having the compositions collated in Table 13.
  • the K tablets contain 56.7% of matrix excipient and contain no alkalinizing agent; the L tablets contain 43.3% of matrix excipient and 13.5% of alkalinizing agent.
  • TABLE 13 Compositions of the K and L tablets. mg/tablet Constituents K L Hydrocodone bitartrate 15 15 Methocel K100M CR 85 65 Na 2 CO 3 , anhydrous — 20 Avicel pH 102 48 48 Aerosil 200 0.5 0.5 Magnesium stearate 1.5 1.5
  • Double-layer tablets containing 15 mg doses of hydrocodone consisting of a controlled-release layer containing a 10 mg dose of hydrocodone and an immediate-release layer containing a 15 mg dose of hydrocodone were prepared in the following manner (M tablets).
  • Controlled-release hydrocodone tablets N and O containing 15 mg doses and containing cellulose acetate as inert matrix excipient were prepared by direct tabletting from homogeneous mixtures having the compositions collated in Table 18.
  • the N tablets contain 54% of inert matrix excipient and 13.3% of alkalinizing agent and the O tablets contain 54% of inert matrix excipient and contain no alkalinizing agent.
  • TABLE 18 Compositions of the N and O tablets. mg/tablet Constituents N O Hydrocodone bitartrate 15 15 Cellulose acetate CA398-10NF 81 81 Emcompass 32 52 Sodium carbonate 20 0 Aerosil 200 0.5 0.5 Magnesium stearate 1.5 1.5
  • Controlled-release hydrocodone tablets P and Q containing 15 mg doses and containing CUTINA HR as lipid matrix excipient were prepared by direct tabletting from homogeneous mixtures having the compositions collated in Table 20.
  • the P tablets contain 30.2% of lipid matrix excipient and 13.3% of alkalinizing agent and the Q tablets contain 30.2% of lipid matrix excipient and contain no alkalinizing agent.
  • Controlled-release hydrocodone tablets R and S containing 15 mg doses and containing a mixture of METHOCEL K100M CR and EUDRAGIT RSPM as matrix excipients were prepared by direct tabletting from homogeneous mixtures having the compositions collated in Table 20.
  • the R tablets contain 43.3% of matrix excipient and 13.3% of alkalinizing agent and the S tablets contain 43.3% of matrix excipient and contain no alkalinizing agent.
  • Controlled-release efletirizine tablets T, U and V containing 30 mg doses were prepared by wet granulation of the active ingredient with emcompress. Their composition is collated in Table 24. TABLE 24 Compositions of the T, U and V tablets. mg/tablet Constituents T U V Efletirizine.2HCl 30 30 30 Methocel K15M CR 70 40 33.3 Emcompress 77 36.3 35 Sodium bicarbonate 20 12 0 Aerosil 200 1 0.7 0.7 Magnesium stearate 2 1 1 Opadry Y1-7000 6 3.6 3
  • Hydrophilic matrices W, X and Y containing 300 mg doses of trapidil containing an alkalinizing agent were prepared by wet granulation of sodium bicarbonate, lactose and povidone; their composition is collated in Table 26. TABLE 26 Compositions of the W, X and Y tablets.
  • the W, X and Y tablets were subjected to a test of bioavailability in man over a period of 24 hours, each volunteer receiving 2 tablets at time 0.
  • the bio-availability profiles obtained with the W, X and Y tablets were compared with the profile obtained by 3 administrations at 6-hour intervals, of 200 mg immediate-release gelatin capsules (reference).
  • the profile was also determined after a single administration of an aqueous solution containing 200 mg of trapidil.
  • oral solution 0, 0.33, 0.5, 0.67, 0.83, 1, 1.5, 2, 4 and 6 hours;
  • gelatin capsule 0, 0.33, 0.67, 1, 2, 4 and 6 hours after each of the 3 administrations,
  • matrix tablets 0, 0.5, 1, 2, 4, 8, 12, 16, 20 and 24 hours.
  • the matrix tablets provide prolonged release of the active substance.
  • the X tablet gives particularly advantageous results with a prolonged t max .
  • the C max is reduced by about 30%, thus avoiding blood concentration peaks, but showing a plateau which extends over more than 12 hours for a practically equivalent absorption of active ingredient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to pharmaceutical compositions which can be administrated orally, allowing the controlled release of at least one active substance comprising
a) the said at least one active substance,
b) between 5 and 60% by weight, relative to the total weight of the composition, of at least one excipient, selected from inert matrices, hydrophilic matrices, lipid matrices, mixtures of inert matrices and of lipid matrices, mixtures of hydrophilic matrices and of inert matrices, with the exception of mixtures comprising a polyacrylic acid and at least one hydrophilic matrix of the cellulose type;
c) between 5 and 50% by weight, relative to the total weight of the composition, of at least one alkalinizing agent soluble in an aqueous phase under physiological pH conditions, selected from alkali or alkaline-earth metal hydroxides, carbonates, bicarbonates and phosphates, sodium borate as well as the basic salts of organic acids.
It also relates to processes for the preparation of said compositions, multi-layered pharmaceutical compositions comprising at least one layer with this composition, as well as processes for the preparation of said multi-layered composition.

Description

  • The present invention relates to pharmaceutical compositions which can be administered orally, allowing the controlled release of pharmaceutically active substances, and to methods of preparing these pharmaceutical compositions. [0001]
  • One of the objectives currently sought in the development of pharmaceutical compositions which can be administered orally is to control the release of pharmaceutically active substances so that they can be administered in a few daily doses, ideally in a single daily dose. [0002]
  • The release of active substances during oral administration can be controlled by means of matrix-type pharmaceutical compositions. Depending on the excipients used, it is possible to identify three types of matrix: inert, hydrophilic and lipophilic matrices. Mixed matrices can also be created by combining excipients for these various types of matrix. [0003]
  • The inert matrices comprise excipients essentially belonging to the class of thermoplastic polymers. They are inert towards biological tissues, other excipients in the formulation and the active substance. They are insoluble and indigestible in the fluids of the gastrointestinal tract. Among these, there may be mentioned polyvinyl chloride, polyethylene, vinyl acetate/vinyl chloride copolymers, polymethylmethacrylates, polyamides, silicones, ethyl cellulose, polystyrene and the like. They generally use a concentration ranging from 20 to 95%. [0004]
  • The hydrophilic matrices comprise gelling excipients which can be divided into three classes: the cellulose derivatives (hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methylcellulose and the like), the noncellulose polysaccharides (galactomannans, guar gum, carob gum, gum arabic, sterculia gum, agar, alginates and the like) and the acrylic acid polymers (carbopols 934P and 974P and the like). They are generally used at a concentration of 20 to 70%. [0005]
  • The lipid matrices comprise four types of fatty excipients: glycerides (mono-, di- or triglycerides: stearin, palmitin, laurin, myristin, hydrogenated castor or cottonseed oils, precirol and the like), fatty acids and alcohols (stearic, palmitic or lauric acids; stearyl, cetyl or cetostearyl alcohols, and the like), fatty acid esters (monostearates of propylene glycol and of sucrose, sucrose distearate and the like) and waxes (white wax, cachalot wax and the like). They are generally used at a concentration of 10 to 50%. [0006]
  • The presence of matrix-type excipients in pharmaceutical compositions makes it possible, in a number of cases, to slow down the release of the active substances by entrapment. However, these matrix-type excipients do not always make it possible to sufficiently slow down the release of the active substance or to obtain the desired ideal release profiles. [0007]
  • For example, when the matrix-type pharmaceutical composition contains a substance which must imperatively be released in the stomach, the release of the active substance over sufficiently long periods depends not only on the type of excipients used in the composition, but also on the residence time of the pharmaceutical composition in the stomach. Accordingly, several documents mention the use of floating matrix tablets. [0008]
  • In particular, patent EP 205336 describes pharmaceutical compositions for the controlled release of active substances comprising a mixed matrix obtained from a mixture of ethers of cellulose and of a polyacrylic acid, of one of its derivatives or of their pharmaceutically acceptable salts, and comprising, in addition, from 10 to 50% by weight, relative to the total weight of matrix excipients, of effervescent foaming agent. The effervescent foaming agent makes it possible to cause the pharmaceutical composition to float in the gastric fluid, thereby increasing the residence time in the stomach. The effervescent foaming agent is an alkali or alkaine-earth metal bicarbonate which is preferably used in combination with an organic acid. [0009]
  • However, the floating in the gastric fluid does not allow other problems observed in the context of the control of the release of active substances from the matrix pharmaceutical compositions to be resolved. [0010]
  • Indeed, the quantities of matrix excipient necessary for adequate prolonged release of the active ingredient can prove to be too high and can make the production of the dosage form impossible or too costly. [0011]
  • Moreover, the release of some active substances greatly depends on the pH. For example, some active substances are not at all released in the stomach, but in other areas of the gastrointestinal tract. In addition, for the same area of the gastrointestinal tract, the release profile will be different depending on whether or not the composition is administered together with a meal. For the active substances whose release depends on the ambient pH, it is therefore desirable to find novel matrix compositions which make it possible to regulate the rate of release so that the active substance can be released at the same rate regardless of the pH of the medium. [0012]
  • Finally, it is very common for the profile of release of an active ingredient from a matrix form to be irregular over time, that is to say that the kinetics of release is not of the zero order but is a function of the square root of the time. A zero order kinetics of release corresponds to a regular and constant release over time and is highly desirable in order to ensure a regular and long-lasting therapeutic effect. [0013]
  • In parallel, it is increasingly therapeutically advantageous to be able to simultaneously administer by the oral route an active substance released immediately after administration, and the same or a second active substance released gradually and regularly after administration. In the case where the same active substance is simultaneously administered for immediate release and for prolonged release, this makes it possible to rapidly release a sufficient dose of active substance to trigger the desired effect and to maintain this effect by a gradual and prolonged release of the same active substance. In the case where an active substance is released immediately and another active substance is released gradually, this males it possible to obtain combined therapeutic effects by means of two active substances having very different pharmacokinetic profiles. [0014]
  • In this context, orally administrable solid pharmaceutical compositions combining, in a single unit, a portion exhibiting immediate release and a portion exhibiting delayed release have been described. However, these compositions require methods of preparation which are technically very sophisticated and/or do not allow the desired release profiles to be obtained for all the active substances. [0015]
  • We have now just discovered, surprisingly, novel pharmaceutical compositions which can be administered orally, allowing the controlled release of pharmaceutically active substances such that a satisfactory therapeutic effect is observed over fairly long periods, for example in only one or even two daily doses. [0016]
  • In particular, the compositions according to the present invention do not require excessive quantities of matrix excipients and allow regular and continuous release of active substances over periods of at least 12 hours. [0017]
  • In addition, we have also just discovered that these new controlled-release pharmaceutical compositions can be used in combination with an immediate-release pharmaceutical composition for the same or for another active substance, in a single unit intended to be administered orally. [0018]
  • The present invention therefore relates to pharmaceutical compositions which can be administered orally, allowing the controlled release of at least one active substance, comprising [0019]
  • a) the said at least one active substance, [0020]
  • b) between 5 and 60% by weight, relative to the total weight of the composition, of at least one excipient, selected from inert matrices, hydrophilic matrices, lipid matrices, mixtures of inert matrices and of lipid matrices, mixtures of hydrophilic matrices and of lipid matrices, mixtures of hydrophilic matrices and of inert matrices, with the exception of mixtures comprising a polyacrylic acid and at least one hydrophilic matrix of the cellulose type; [0021]
  • c) between 5 and 50% by weight, relative to the total weight of the composition, of at least one alkalinizing agent soluble in an aqueous phase under physiological pH conditions, selected from alkali or alkaline-earth metal hydroxides, carbonates, bicarbonates and phosphates, sodium borate as well as the basic salts of organic acids.[0022]
  • The present invention is in particular illustrated by FIGS. [0023] 1 to 5:
  • FIG. 1: pseudoephedrine bioavailability profiles obtained with cetirizine (immediate release)/pseudoephedrine (controlled release) bilayer tablets; [0024]
  • FIG. 2: kinetics of in vitro release of trapidil; matrix tablets without alkalinizing agent: [0025]
  • FIG. 3: kinetics of in vitro release of trapidil; matrix tablets with alkalinizing agent; [0026]
  • FIG. 4: kinetics of in vitro release of hydrocodones; matrix tablets with and without alkalinizing agent; [0027]
  • FIG. 5: profiles of bioavailability of trapidil obtained with coated matrix tablets.[0028]
  • The pharmaceutical compositions according to the present invention comprise matrix excipients chosen from inert, hydrophilic and lipophilic matrices. [0029]
  • Examples of inert matrices which can be used according to the present invention are: polyvinyl chloride, polyethylene, vinyl acetate/vinyl chloride copolymers, polymethylmethacrylates, polyamides, silicones, ethyl cellulose, polystyrene and the like. [0030]
  • Examples of hydrophilic matrices which can be used according to the present invention are: cellulose derivatives (hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methylcellulose and the like), noncellulose polysaccharides (galactomannans, guar gum, carob gum, gum arabic, sterculia gum, agar, alginates and the like) and acrylic acid polymers (carbopols 934P and 974P and the like). The hydrophilic matrices preferably used according to the present invention are hydroxypropyl celluloses, such as METHOCEL K or E. The content of hydroxypropyl methylcellulose-type excipients in the compositions according to the present invention is preferably between 5 and 60% by weight relative to the total weight of the composition. [0031]
  • Examples of lipid matrices which can be used according to the present invention are: glycerides (mono-, di- or triglycerides: stearin, palmitin, laurin, myristin, hydrogenated castor or cottonseed oils, precirol and the like), fatty acids and alcohols (stearic acid, palmitic acid, lauric acid; stearyl alcohol, cetyl alcohol, cetostearyl alcohols, and the like), fatty acid esters (monostearates of propylene glycol and of sucrose, sucrose distearate and the like) and waxes (white wax, cachalot wax and the like). [0032]
  • The matrix excipients may also be in the form of a mixture. However, the pharmaceutical compositions of the invention do not comprise mixtures comprising a polyacrylic acid and at least one hydrophilic matrix of the cellulose type. [0033]
  • The alkalinizing agent which can be used according to the present invention should be soluble in the aqueous phase under physiological pH conditions so as to produce the desired effect. The alkalinizing agent may be chosen from alkali or alkaline-earth metal hydroxides, carbonates, bicarbonates and phosphates, sodium borate as well as basic salts of organic acids (example: sodium citrate). On the other hand, salts not soluble in water under physiological pH conditions, such as magnesium stearate or dibasic calcium phosphate, are not suitable according to the present invention. [0034]
  • The quantity of alkalinizing agent present in the pharmaceutical compositions according to the present invention is ideally from 5 to 50% by weight relative to the total weight of the composition. [0035]
  • As regards the active substances which may be present in the compositions according to the present invention, they may be of a wide variety of types. [0036]
  • They may be chosen from vasoconstrictors, antihistamines, analgesics, antitussives and the like. The applicant has in particular observed that the invention is particularly suited to active substances whose free base is less soluble in water than its pharmaceutically acceptable salts. Nonlimiting examples of such active substances are pseudoephedrine, ephedrine, phenylephrine, phenylpropanolamine, trapidil, hydrocodone, cetirizine, efletirizine, hydroxyzine, meclozine, buclizine, pentoxyverine, codeine, morphine, their optical isomers or their pharmaceutically acceptable salts. [0037]
  • As regards the dose of active substance used, it depends on the effective dose and may therefore vary within very wide limits depending on the said active substance. [0038]
  • In addition to the above-mentioned components, the pharmaceutical compositions according to the present invention may also contain other excipients such as diluents (example: emcompress, lactose and the like), binders (avicel, starches, polyvinylpyrrolidone and the like), disintegrants (starches and modified starches, cellulose derivatives, alginic derivatives, pectins and the like), lubricants (talc, magnesium stearate, colloidal silica and the like), taste-masking agents (α-cyclodextrin, β-cyclodextrin, γ-cyclodexin and their alkylated derivatives), flavourings or colourings as well as coaling agents (example: cellulose derivatives, methacrylic resins, polyvinyl chloride, nylons and the like). [0039]
  • The pharmaceutical composition is according to the present invention are generally provided in a solid form. It is important to underline that the beneficial effects of the invention are observed regardless of the presentation of the galenic form. The pharmaceutical compositions according to the present invention are provided in the form of tablets, granules, microgranules and the like, these forms being coated or otherwise. [0040]
  • The controlled-release pharmaceutical compositions according to the present invention can be prepared by various conventional methods known to persons skilled in the art. [0041]
  • Generally, the pharmaceutical compositions according to the present invention are prepared by a process comprising the following successive steps: [0042]
  • i. preparation of a homogeneous mixture containing components a, b and c and the other excipients optionally present; [0043]
  • ii. tabletting of the homogeneous mixture obtained in step i, optionally after granulation. [0044]
  • The tabletting may be of various types and is ideally carried out by direct tabletting. The optional granulation in step ii may be carried out either by the wet route or by the dry route, or alternatively by melt-granulation. [0045]
  • According to a specific embodiment of the invention, the controlled-release pharmaceutical compositions according to the invention are used in combination with one or more pharmaceutical compositions allowing immediate release of active substances. When these two types of compositions are present in the same unit, this makes it possible to obtain, in a single administration, both the immediate release of a first active substance and the prolonged release of the same or of a second active substance. [0046]
  • Accordingly, the present invention also relates to pharmaceutical compositions which can be administered orally, comprising [0047]
  • A. at least one layer comprising an active substance and excipients which allow immediate release of the said active substance after administration, and [0048]
  • B. at least a second layer which allows the controlled release of the same or of a second active substance, comprising the said same or second active substance, at least one matrix-type excipient and at least one alkalinizing agent. [0049]
  • As regards layer A, the excipients allowing immediate release of the active substance may be chosen from diluents (encompress, lactose and the like), binders (Avicel, starches, polyvinylpyrrolidone and the like), disintegrants (starches and modified starches, cellulose derivatives, alginic derivatives, pectins and the like), lubricants (talc, magnesium stearate, colloidal silica and the like), taste-masking agents (α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin and their alkylated derivatives), flavourings or colourings. [0050]
  • Such combined pharmaceutical compositions can be prepared according to various methods known to persons skilled in the art. [0051]
  • More particularly, these combined pharmaceutical compositions may be provided in the form of a tablet in which at least one layer A is stuck to at least one layer B. In this case, such pharmaceutical compositions may be prepared by a process comprising the following successive steps: [0052]
  • 1) preparation of separate homogeneous mixtures from the components of layers A and B, and [0053]
  • 2) tabletting of the homogeneous mixtures obtained in 1) in a multilayer tabletting machine. [0054]
  • Optionally, the tabletting step 2) may be preceded by a step of granulating the homogeneous mixtures obtained in step 1). [0055]
  • The multilayer tabletting machines which make it possible to prepare this type of tablet are Courtoy, Manesty, Hata, Fette, Killian type multilayer tabletting machines and the like. [0056]
  • The multilayer tablets are particularly well suited to cases of combinations of active substances for which very specific beneficial therapeutic effects have recently been obtained, for example, pseudoephedrine/cetirizine, hydrocodone/acetaminophen, immediate release hydrocodone/prolonged release hydrocodone. [0057]
  • The following examples illustrate the present invention without, however, limiting it. In the examples which follow, the percentages are expressed by weight relative to the total weight of the compositions. [0058]
    • EXAMPLE 1 Reducing the Quantity of Matrix Excipient
  • Controlled-release pseudoephedrine tablets A, B and C containing 120 mg doses were prepared by direct tabletting from homogeneous mixtures having, respectively, the compositions presented in Table 1. [0059]
  • The A tablets contain 16% of matrix excipient and 14.25% of alkalinizing agent. They have a mean weight of 281.03 mg and a hardness of 104 N. [0060]
  • The B and C tablets, for their part, contain no alkalinizing agent and contain 40% and 50% of matrix excipient respectively. They have a mean weight of 298.3 mg and 402.25 mg respectively, and their respective degrees of hardness are 118 N and 137 N. [0061]
    TABLE 1
    Composition of the A, B and C tablets
    mg/tablet
    Constituents A B C
    Pseudoephedrine.HCl
    120 120 120
    Methocel K15M CR 45 120 —
    Methocel K100M CR — — 200
    Na2CO3, anhydrous 40 — —
    Avicel pH 102 70.8 55.5 74
    Aerosil 200 1.4 1.5 2
    Magnesium stearate 2.8 3 4
  • The kinetics of release of pseudoephedrine from these 3 types of tablet was determined in vitro with the aid of the [0062] USP 23 dissolution apparatus No. 1 (23rd edition of the American Pharmacopoeia). The tablets are placed in the basket which is subjected to 50 revolutions per minute. The dissolution medium consists of 500 ml of distilled water kept at 37° C. Every hour, for 12 hours, a sample is taken from the dissolution medium and the pseudoephedrine is assayed by HPLC. The results of these assays are presented in Table 2.
    TABLE 2
    Percentage release of pseudoephedrine.
    Time (h) A B C
    0 0 0 0
    1 31.87 41.56 38.81
    2 46.04 57.89 51.69
    3 56.4 71.4 62.43
    4 65.07 81.43 72.02
    5 75.41 86.34 77.65
    6 75.95 90.44 83.53
    7 77.7 93.01 85.21
    8 79.6 94.16 88.48
    10 82.82 96.21 92.16
    12 85.36 94.05 93.07
  • The results of Table 2 show that fairly similar release profiles are observed in the three cases, the slowest release being observed for the A tablets. This shows that a very good control of release can be obtained with less matrix excipient when an alkalinizing agent is present in the composition. [0063]
  • The A, B and C tablets were also the subject of a test of bioavailability in man over a period of 32 hours. In this test, the profiles of bioavailability obtained with the A, B and C tablets were compared with the bioavailability profile obtained by administering immediate release gelatin capsules of pseudoephedrine containing 60 mg doses, administered after an interval of 6 hours. [0064]
  • Eight healthy subjects (18 to 45 year old men) participated in this crossover study, each subject receiving 4 forms with a “wash-out” period of 7 days between the two administrations. Blood samples were taken from the subjects over 32 hours according to the following schemes: [0065]
  • matrix tablets: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24 and 32 hours; [0066]
  • gelatin capsules: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 16, 24 and 32 hours. [0067]
  • The pseudoephedrine levels were determined by a validated HPLC method (UV detection). [0068]
  • The results of this bioavailability study are presented in FIG. 1 and in Table 3, in which AUC represents the area under the curve, C[0069] max represents the maximum concentration detected and Tmax represents the time necessary to obtain Cmax.
    TABLE 3
    Bioavailability of pseudoephedrine in man.
    Tablets
    Gelatin capsules (120 mg)
    (2 × 60 mg) A B C
    AUC (μg · h/ml) 3672 4019 4028 3683
    Cmax (μg/ml) 391 276 295 259
    Tmax (h) 1.5 4.5 5.0 5.0
  • The results of this bioavailability study show that much more regular release profiles are obtained with pharmaceutical compositions comprising matrix excipients containing 120 mg doses compared with that obtained with two administrations of immediate-release tablets containing 60 mg doses. [0070]
  • Moreover, the active substance is released in a comparable manner for the A, B and C tablets. This example illustrates the fact that, to obtain an adequate prolonged release of the active substance, a much smaller quantity of matrix excipient (16% instead of 40% or 50%) is sufficient when this excipient is combined with an alkalinizing agent. [0071]
    • EXAMPLE 2 Effect of Coating
  • Controlled-release pseudoephedrine tablets containing 120 mg doses and containing 15.4% of Methocel K15M CR and 13.7% of sodium carbonate were prepared by direct tabletting from a homogeneous mixture having the composition presented in Table 4 (D tablets). [0072]
    TABLE 4
    D Tablets.
    Constituents mg/tablet
    Pseudoephedrine.HCl
    120
    Methocel K15M CR 45
    Na2CO3, anhydrous 40
    Avicel pH 102 82.5
    Aerosil 200 1.4
    Magnesium stearate 2.8
  • The D tablets have a mean weight of 292.5 mg. A portion of these tablets was coated with Opadry OY-B-28920 (polyvinyl alcohol, lecithin, xanthan gum, titanium dioxide, talc). The kinetics of in vitro release of pseudoephedrine from the coated or uncoated D tablets was determined in the same manner as in Example 1. The results are presented in Table 5. [0073]
    TABLE 5
    Percentage release of pseudoephedrine.
    Time (h) Uncoated Coated
    0 0 0
    1 33.7 30.4
    2 47.5 45.6
    3 57.9 56.5
    4 65.8 65.7
    5 71.9 72.0
    6 77.1 76.8
    7 80.7 80.2
    8 83.4 83.1
    • EXAMPLE 3 Effect of Various Alkalinizing Agents
  • Controlled-release pseudoephedrine tablets containing 180 mg doses and containing 30% of Methocel K15M CR and 30% of sodium carbonate (E), sodium bicarbonate (F) or potassium hydrogen phosphate (G) were prepared by direct tabletting from homogeneous mixtures having the compositions presented in Table 6. [0074]
    TABLE 6
    E, F and G tablets.
    mg/tablet
    Constituents E F G
    Pseudoephedrine.HC1 180 180 180
    Methocel K15M CR 180 180 180
    Na2CO3, anhydrous 180 — —
    NaHCO3 — 180 —
    K2HPO4 — — 180
    Avicel pH 102 51 51 51
    Aerosil 200 3 3 3
    Magnesium stearate 6 6 6
  • The kinetics of in vitro release of pseudoephedrine for the E, F and G tablets, obtained in the same manner as in Example 1 with the baskets rotating at 100 rpm, are collated in Table 7. [0075]
    TABLE 7
    Percentage release of pseudoephedrine.
    Time(h) E F G
    0 0 0 0
    1 17.1 29.2 28.9
    2 23.3 45.6 45.2
    3 28.9 57.7 56.2
    4 34.5 67.3 65.1
    5 39.1 74.9 73.3
    6 44.1 81.6 79.8
    7 49.2 86.1 85.2
    • EXAMPLE 4 Pseudoephedrine/cetirizine Double-layer Tablets
  • Double-layer tablets containing 120 mg doses of controlled-release pseudoephedrine and 5 mg of immediate-release cetirizine were prepared in the following manner (H tablets). [0076]
  • Two separate homogeneous mixtures (H[0077] A and HB) were prepared from the presented in Tables 8 and 9.
  • Mixtures H[0078] A and HB were then tabletted in a multilayer tabletting machine to give double-layer tablets in which the layers are stuck to each other. These tablets were then coated with Opadry OY-B-28920 (polyvinyl alcohol, lecithin, xanthan gum, titanium dioxide, talc).
  • In these tablets, the prolonged-release layer contains 16.1% of matrix excipient and 14.3% of sodium carbonate. [0079]
    TABLE 8
    Mixture HA.
    Constituents mg/tablet
    Cetirizine.2HC1
    5
    Tablettose 41.3
    Avicel pH 102 22.65
    Aerosil 200 0.35
    Magnesium stearate 0.7
  • [0080]
    TABLE 9
    Mixture HB.
    Constituents mg/tablet
    Pseudoephedrine.HCl
    120
    Methocel K15M CR 45
    Na2CO3, anhydrous 40
    Aerosil 200 1.4
    Magnesium stearate 2.8
  • The kinetics of in vitro release of pseudoephedrine and of cetirizine for the H tablets, obtained in the same manner as in Example 1 with baskets rotating at 100 rpm, are collated in Table 10. [0081]
    TABLE 10
    Percentage release of pseudoephedrine and cetirizine.
    Time (h) Pseudoephedrine Cetirizine
    0 0 0
    0.25 11.2 80.2
    0.5 21.4 82.7
    0.75 32.0 86.0
    1 37.8 86.6
    2 58.2 89.7
    4 83.7 93.4
    6 97.9 97.5
    8 102.4 99.5
    10 104.6 101.2
    12 105.8 101.8
    • EXAMPLE 5 Effect of the pH
  • Controlled-release trapidil tablets I and J containing 300 mg doses were prepared by direct tabletting from homogeneous mixtures having the compositions collated in Table 11. [0082]
  • The I and J tablets contain 33.3% of matrix excipient; the I tablets contain no alkalinizing agent and the J tablets contain 12.5% of alkalinizing agent. [0083]
    TABLE 11
    Compositions of the I and J tablets.
    mg/tablet
    Constituents I J
    Trapidil
    300 300
    Methocel K100M CR 200 200
    Na2CO3, anhydrous — 75
    Avicel pH 102 91 16
    Aerosil 200 3 3
    Magnesium stearate 6 6
  • The mean weights and the degrees of hardness of the I and J tablets are 605.3 mg and 125 N (I) and 597.7 mg and 79 N (J), respectively. The kinetics of in vitro release of trapidil were determined according to the method described in Example 1 using two dissolution media: a 0.1 N solution of hydrochloric acid and a solution of phosphate buffer at pH 7.5. The speed of rotation of the baskets was 100 rpm. The results of this study are presented in Table 12, as well as in FIGS. 2 and 3. [0084]
    TABLE 12
    Percentage release of trapidil as a function of the ambient pH
    0.1 N HCl Buffer pH 7.5
    Time (h) I J I J
    0 0 0 0 0
    1 26.7 12.5 13.5 13.8
    2 39.5 21.4 20.8 21.9
    3 49.6 29.3 26.6 28.4
    4 58.2 36.3 31.6 33.8
    5 64.9 42.3 35.9 38.7
    6 71.2 47.8 40.1 43.1
    7 76.8 53.2 43.3 46.9
    8 83.1 59.1 45.7 50.5
    10 90.4 67.7 53.5 57.2
    12 94.6 74.6 59.1 62.6
    15 100.5 86.3 67.0 70.2
    17 100.0 89.9 70.9 73.8
  • FIG. 2 and the results presented in Table 12 for the I tablets show that these tablets exhibit very different release kinetics depending on the pH. These results show that a controlled and prolonged release cannot be obtained in a strongly acidic medium when there is no alkalinizing agent in the pharmaceutical composition. [0085]
  • FIG. 3 and the results presented in Table 12 for the J tablets show that a prolonged release of the active substance may very well be obtained in a strongly acidic medium when an alkalinizing agent Is present in the pharmaceutical composition. [0086]
    • EXAMPLE 6 Linearization of the Kinetics of Release
  • Controlled-release hydrocodone tablets K and L containing 15 mg doses were prepared by direct tabletting from homogeneous mixtures having the compositions collated in Table 13. The K tablets contain 56.7% of matrix excipient and contain no alkalinizing agent; the L tablets contain 43.3% of matrix excipient and 13.5% of alkalinizing agent. [0087]
    TABLE 13
    Compositions of the K and L tablets.
    mg/tablet
    Constituents K L
    Hydrocodone bitartrate
    15 15
    Methocel K100M CR 85 65
    Na2CO3, anhydrous — 20
    Avicel pH 102 48 48
    Aerosil 200 0.5 0.5
    Magnesium stearate 1.5 1.5
  • The kinetics of in vitro release of hydrocodone from the K and L tablets were determined with the aid of the [0088] USP 23 dissolution apparatus No. 2. The tablets are placed in the dissolution container. The speed of rotation of the paddles is 100 revolutions per minute. The dissolution medium consists of 500 ml of a phosphate buffer solution at pH 5.8. Samples were taken over 12 hours from the dissolution medium and the hydrocodone is assayed by HPLC. The results of this study are presented in Table 14 and FIG. 4.
    TABLE 14
    Percentage release of hydrocodone.
    Time (h) K L
    0 0 0
    1 24.9 5.4
    2 41.8 9.2
    4 65.0 17.7
    6 80.7 31.5
    8 91.5 45.8
    10 97.8 57.6
    12 103.7 63.1
  • The results presented in Table 14 show that the presence of alkalinizing agent in the composition slows the release of the active substance. In addition, as shown in FIG. 4, the kinetics of release is linearized, that is to say that the rate of release remains constant over time. [0089]
  • Another test carried out under similar conditions and by assaying the hydrocodone by UV spectroscopy also showed a constant rate of release over 18 hours. Furthermore, the release of the active substance was complete after 18 hours. [0090]
    • EXAMPLE 7 Hydrocodone/hydrocodone Double-layer Tablets
  • Double-layer tablets containing 15 mg doses of hydrocodone consisting of a controlled-release layer containing a 10 mg dose of hydrocodone and an immediate-release layer containing a 15 mg dose of hydrocodone were prepared in the following manner (M tablets). [0091]
  • Two separate homogeneous mixtures (M[0092] A and MB) were prepared from the compositions presented in Tables 15 and 16.
  • The mixtures M[0093] A and MB were then tabletted in a multilayer tabletting machine to give double-layer tablets in which the two layers are stuck to each other. In these tablets, the prolonged-release layer contains 43.3% of Methocel K100M CR and 13.3% of sodium carbonate.
    TABLE 15
    Mixture MA.
    Constituents mg/tablet
    Hydrocodone bitartrate
    5
    Tablettose 28.2
    Avicel pH 102 16.1
    Aerosil 200 0.3
    Magnesium stearate 0.4
  • [0094]
    TABLE 16
    Mixture MB.
    Constituents mg/tablet
    Hydrocodone bitartrate
    10
    Methocel K100M CR 43.3
    Na2CO3, anhydrous 13.3
    Avicel pH 102 32.1
    Aerosil 200 0.3
    Magnesium stearate 1
  • The kinetics of in vitro release of hydrocodone for the M tablets were determined with the aid of the [0095] USP 23 dissolution apparatus No. 1. The speed of rotation of the baskets was 100 revolutions per minute. The dissolution medium consisted of 500 ml of a phosphate buffer solution at pH 5.8. The hydrocodone was assayed as in Example 6. The results are presented in Table 17.
    TABLE 17
    Percentage release of hydrocodone.
    Time (h) Hydrocodone
    0 0
    1 35.0
    2 41.5
    4 64.6
    6 82.2
    8 89.1
    10 94.3
    12 101.0
  • The results presented in Table 17 show that 35% of hydrocodone was already released after 1 hour, which corresponds to the hydrocodone content in the immediate-release layer (33.3% of the total dose). Next, the release of hydrocodone continues gradually and regularly according to a kinetics comparable to that observed in Example 6. [0096]
    • EXAMPLE 8 Hydrocodone-inert Matrix Tablets
  • Controlled-release hydrocodone tablets N and O containing 15 mg doses and containing cellulose acetate as inert matrix excipient were prepared by direct tabletting from homogeneous mixtures having the compositions collated in Table 18. The N tablets contain 54% of inert matrix excipient and 13.3% of alkalinizing agent and the O tablets contain 54% of inert matrix excipient and contain no alkalinizing agent. [0097]
    TABLE 18
    Compositions of the N and O tablets.
    mg/tablet
    Constituents N O
    Hydrocodone bitartrate
    15 15
    Cellulose acetate CA398-10NF 81 81
    Emcompass 32 52
    Sodium carbonate 20 0
    Aerosil 200 0.5 0.5
    Magnesium stearate 1.5 1.5
  • The kinetics of release of hydrocodone from these two types of tablet was determined in vitro with the aid of the [0098] USP 23 dissolution apparatus No. 1. The tablets are placed in the basket which is subjected to 100 revolutions per minute. The dissolution medium consisted of 500 ml of a phosphate buffer solution at pH 5.8. The hydrocodone was assayed as in Example 6. The results are presented in Table 19.
    TABLE 19
    Percentage release of hydrocodone.
    Hydrocodone
    Time (h) N O
    0 0 0
    1 9.57 48.88
    2 21.44 78.24
    4 27.61 91.24
    6 34.05 100.94
    8 51.93 101.07
    10 58.44 95.60
    12 81.21 99.64
  • The results presented in Table 19 show that the presence of alkalinizing agent in the composition slows the release of the active substance. In addition, as in Example 6, the kinetics of release is linearized. [0099]
    • EXAMPLE 9 Hydrocodone-lipid Matrix Tablets
  • Controlled-release hydrocodone tablets P and Q containing 15 mg doses and containing CUTINA HR as lipid matrix excipient were prepared by direct tabletting from homogeneous mixtures having the compositions collated in Table 20. The P tablets contain 30.2% of lipid matrix excipient and 13.3% of alkalinizing agent and the Q tablets contain 30.2% of lipid matrix excipient and contain no alkalinizing agent. [0100]
    TABLE 20
    Compositions of the P and Q tablets.
    mg/tablet
    Constituents P Q
    Hydrocodone bitartrate
    15 15
    Cutina HR 45.3 45.3
    Avicel pH 102 67.8 87.7
    Sodium carbonate 20 0
    Aerosil 200 0.5 0.5
    Magnesium stearate 1.5 1.5
  • The kinetics of release of hydrocodone from these two types of tablet was determined in vitro with the aid of the [0101] USP 23 dissolution apparatus No. 1. The tablets are placed in the basket which is subjected to 100 revolutions per minute. The dissolution medium consisted of 500 ml of a phosphate buffer solution at pH 5.8. The hydrocodone was assayed as in Example 6. The results are presented in Table 21.
    TABLE 21
    Percentage release of hydrocodone.
    Hydrocodone
    Time (h) P Q
    0 0 0
    1 5.91 58.76
    2 12.50 84.46
    3 23.05 91.96
    4 29.01 91.47
    6 52.07 101.84
    8 68.96 102.63
    10 80.92 103.37
    12 90.73 104.92
  • The results presented in Table 21 show that the presence of alkalinizing agent in the composition slows the release of the active substance. In addition, as in Example 6, the kinetics of release is linearized. [0102]
    • EXAMPLE 10 Hydrocodone-mixed Matrix Tablets
  • Controlled-release hydrocodone tablets R and S containing 15 mg doses and containing a mixture of METHOCEL K100M CR and EUDRAGIT RSPM as matrix excipients were prepared by direct tabletting from homogeneous mixtures having the compositions collated in Table 20. The R tablets contain 43.3% of matrix excipient and 13.3% of alkalinizing agent and the S tablets contain 43.3% of matrix excipient and contain no alkalinizing agent. [0103]
    TABLE 22
    Compositions of the R and S tablets.
    mg/tablet
    Constituents R S
    Hydrocodone bitartrate
    15 15
    Methocel K100M CR 52.5 52.5
    Eudragit RSPM 12.5 12.5
    Avicel pH 102 48 68
    Sodium carbonate 20 0
    Aerosil 200 0.5 0.5
    Magnesium stearate 1.5 1.5
  • The kinetics of release of hydrocodone from these two types of tablet was determined in vitro with the aid of the [0104] USP 23 dissolution apparatus No. 1. The tablets are placed in the basket which is subjected to 100 revolutions per minute. The dissolution medium consisted of 500 ml of a phosphate buffer solution at pH 5.8. The hydrocodone was assayed as in Example 6. The results are presented in Table 23.
    TABLE 23
    Percentage release of hydrocodone.
    Hydrocodone
    Time (h) R S
    0 0 0
    1 9.10 26.05
    2 18.12 42.80
    3 27.81 49.76
    4 38.13 59.32
    6 63.41 70.16
    8 81.76 78.13
    10 88.12 83.22
    12 101.69 88.73
  • The results presented in Table 23 show that the presence of alkalinizing agent in the composition slows the release of the active substance. In addition, as in Example 6, the kinetics of release is linearized. [0105]
    • EXAMPLE 11 Coated Matrix Tablets of Efletrizine
  • Controlled-release efletirizine tablets T, U and V containing 30 mg doses were prepared by wet granulation of the active ingredient with emcompress. Their composition is collated in Table 24. [0106]
    TABLE 24
    Compositions of the T, U and V tablets.
    mg/tablet
    Constituents T U V
    Efletirizine.2HCl
    30 30 30
    Methocel K15M CR 70 40 33.3
    Emcompress 77 36.3 35
    Sodium bicarbonate 20 12 0
    Aerosil 200  1 0.7 0.7
    Magnesium stearate  2 1 1
    Opadry Y1-7000  6 3.6 3
  • The kinetics of release of efletirizine from these three types of tablet was determined in vitro with the aid of the [0107] USP 23 dissolution apparatus No. 1. The tablets are placed in the basket which is subjected to 100 revolutions per minute. Three dissolution media were tested: water and buffered solutions at pH 4.5 and 7.5. The efletirizine was assayed by HPLC for the buffer solution at pH 4.5 and by UV spectroscopy for the other solutions. The results are given in Table 25.
    TABLE 25
    Percentage release of efletirizine.
    Efletirizine
    T U V
    Time (h) pH 4.5 Water pH 7.5 pH 4.5 Water pH 7.5 pH 4.5 Water pH 7.5
    0 0 0 0 0 0 0 0 0 0
    1 11.79 10.35 15.70 25.97 17.83 36.82 17.67 20.07 13.12
    2 20.18 18.83 25.77 35.36 29.32 48.33 18.04 36.15 22.04
    4 35.47 33.07 41.47 51.97 48.38 63.88 29.47 54.13 37.40
    6 47.82 44.88 53.80 65.44 62.62 75.90 39.18 71.23 50.82
    8 59.05 54.85 64.10 75.70 74.68 84.48 49.17 85.08 62.16
    12 75.84 70.97 80.37 91.40 90.25 96.57 67.55 97.37 80.69
    16 87.23 82.88 91.73 100.64 100.32 104.03 89.74 102.45 93.58
    24 102.62 98.08 104.72 106.47 104.95 109.42 105.35 102.27 104.21
  • The results presented in Table 25 show that for the V tablet, which contains no alkalinizing agent, the kinetics of release is strongly dependent on the pH. For the other two types of tablet, this difference is greatly reduced. [0108]
    • EXAMPLE 12 Coated Matrix Tablets of Trapidil
  • Hydrophilic matrices W, X and Y containing 300 mg doses of trapidil containing an alkalinizing agent were prepared by wet granulation of sodium bicarbonate, lactose and povidone; their composition is collated in Table 26. [0109]
    TABLE 26
    Compositions of the W, X and Y tablets.
    mg/tablet
    Constituents W X Y
    Trapidil
    300  300 300 
    Methocel K15M CR  0 0 200 
    Methocel E4M CR 150  0  0
    Natrosol 250 HHX  0 150  0
    Sodium bicarbonate 60 60 60
    Avicel PH 101 50 100.8  0
    Lactose 100 mesh 32 32 32
    Aerosil standard  3 3.25  3
    Magnesium stearate  3 1.95  3
    Povidone K30  2 2  2
    Opadry Y1-7000 18 20 18
  • The W, X and Y tablets were subjected to a test of bioavailability in man over a period of 24 hours, each volunteer receiving 2 tablets at [0110] time 0. The bio-availability profiles obtained with the W, X and Y tablets were compared with the profile obtained by 3 administrations at 6-hour intervals, of 200 mg immediate-release gelatin capsules (reference). The profile was also determined after a single administration of an aqueous solution containing 200 mg of trapidil.
  • Eight healthy subjects (18 to 45 year old men) participated in this crossover study, each subject receiving the 5 forms with a “wash-out” period of 7 days between two administrations. [0111]
  • Blood samples were collected from the subjects over 24 hours according to the following schemes: [0112]
  • oral solution: 0, 0.33, 0.5, 0.67, 0.83, 1, 1.5, 2, 4 and 6 hours; [0113]
  • gelatin capsule: 0, 0.33, 0.67, 1, 2, 4 and 6 hours after each of the 3 administrations, [0114]
  • matrix tablets: 0, 0.5, 1, 2, 4, 8, 12, 16, 20 and 24 hours. [0115]
  • The results of this study are presented in FIG. 5 and in Table 27, in which AUC represents the area under the curve, C[0116] max represents the maximum concentration detected and tmax represents the time necessary to obtain Cmax.
    TABLE 27
    Bioavailability of trapidil in man.
    Tablets
    Gelatin capsules W X Y
    AUC0-24h (μg · h/ml) 74.3 64.9 69.4 55.7
    Cmax (μg/ml) 7.55 5.05 5.07 4.34
    Tmax (h) 1 4 10 3
  • The results of this study show that the matrix tablets provide prolonged release of the active substance. Compared with the multiple administration of rapid-release gelatin capsules, the X tablet gives particularly advantageous results with a prolonged t[0117] max. The Cmax is reduced by about 30%, thus avoiding blood concentration peaks, but showing a plateau which extends over more than 12 hours for a practically equivalent absorption of active ingredient.

Claims (10)

1. Pharmaceutical composition which can be administered orally, allowing the controlled release of at least one active substance comprising
a) the said at least one active substance,
b) between 5 and 60% by weight, relative to the total weight of the composition, of at least one excipient, selected from inert matrices, hydrophilic matrices, lipid matrices, mixtures of inert matrices and of lipid matrices, mixtures of hydrophilic matrices and of inert matrices, with the exception of mixtures comprising a polyacrylic acid and at least one hydrophilic matrix of the cellulose type;
c) between 5 and 50% by weight, relative to the total weight of the composition, of at least one alkalinizing agent soluble in an aqueous phase under physiological pH conditions, selected from alkali or alkaline-earth metal hydroxides, carbonates, bicarbonates and phosphates, sodium borate as well as the basic salts of organic acids.
2. Pharmaceutical composition according to claim 1, characterized in that the active substance is chosen from pseudoephedrine, efletirizine, trapidil and hydrocodone, their optical isomers or their pharmaceutically acceptable salts.
3. Pharmaceutical composition according to either of claims 1 and 2, characterized in that the matrix excipient is of the hydroxypropyl methylcellulose type.
4. Pharmaceutical composition according to any one of claims 1 to 3, characterized in that it comprises, in addition, one or more other pharmaceutically acceptable excipients.
5. Pharmaceutical composition according to claim 3, characterized in that the said one or more other pharmaceutically acceptable excipients is chosen from diluents, binders, disintegrants, lubricants, taste-masking agents, flavourings, colourings or coating agents.
6. Process for preparing a pharmaceutical composition according to any one of claims 1 to 5, characterized in that it comprises the following successive steps:
i. preparation of a homogeneous mixture containing components a, b and c and the other excipients optionally present;
ii. tabletting of the homogeneous mixture obtained in step i, optionally after granulation.
7. Pharmaceutical composition which can be administered orally, allowing the immediate release of a first active substance and the prolonged release of the same or of a second active substance, comprising
A. at least one layer comprising an active substance and excipients which allow immediate release of the said active substance after administration, and
B. at least one second layer which allows the controlled release of the same or of a second active substance, this layer being a pharmaceutical composition according to any one of claims 1 to 5.
8. Pharmaceutical composition according to claim 7, characterized in that the immediate-release layer A is stuck to the prolonged-release layer B.
9. Process for the preparation of a pharmaceutical composition according to claim 7, characterized in that it comprises the following successive steps:
(1) preparation of separate homogeneous mixtures from the components of layers A and B, and
(2) tabletting of the mixtures obtained in 1) in a multilayer tabletting machine.
10. Process of preparation according to claim 9, characterized in that the tabletting step 2) is preceded by a step of granulating the homogeneous mixtures obtained in step 1).
US10/055,962 1997-03-14 2002-01-28 Pharmaceutical compositions for the controlled release of active substances Abandoned US20020110596A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/055,962 US20020110596A1 (en) 1997-03-14 2002-01-28 Pharmaceutical compositions for the controlled release of active substances
US10/607,047 US7083807B2 (en) 1997-03-14 2003-06-27 Pharmaceutical compositions for the controlled release of active substances

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
BE9700225 1997-03-14
BE9700225A BE1011045A3 (en) 1997-03-14 1997-03-14 Pharmaceutical composition for controlled release of active substances.
US09/381,044 US6699502B1 (en) 1997-03-14 1998-03-13 Pharmaceutical compositions for controlled release of active substances
US10/055,962 US20020110596A1 (en) 1997-03-14 2002-01-28 Pharmaceutical compositions for the controlled release of active substances

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US09381044 Continuation 1998-03-13
PCT/BE1998/000033 Continuation WO1998041194A1 (en) 1997-03-14 1998-03-13 Pharmaceutical compositions for controlled release of active substances
US09/381,044 Continuation US6699502B1 (en) 1997-03-14 1998-03-13 Pharmaceutical compositions for controlled release of active substances

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/607,047 Continuation US7083807B2 (en) 1997-03-14 2003-06-27 Pharmaceutical compositions for the controlled release of active substances

Publications (1)

Publication Number Publication Date
US20020110596A1 true US20020110596A1 (en) 2002-08-15

Family

ID=3890403

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/381,044 Expired - Lifetime US6699502B1 (en) 1997-03-14 1998-03-13 Pharmaceutical compositions for controlled release of active substances
US10/055,962 Abandoned US20020110596A1 (en) 1997-03-14 2002-01-28 Pharmaceutical compositions for the controlled release of active substances
US10/607,047 Expired - Lifetime US7083807B2 (en) 1997-03-14 2003-06-27 Pharmaceutical compositions for the controlled release of active substances

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/381,044 Expired - Lifetime US6699502B1 (en) 1997-03-14 1998-03-13 Pharmaceutical compositions for controlled release of active substances

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/607,047 Expired - Lifetime US7083807B2 (en) 1997-03-14 2003-06-27 Pharmaceutical compositions for the controlled release of active substances

Country Status (20)

Country Link
US (3) US6699502B1 (en)
EP (1) EP1007005B1 (en)
JP (1) JP2001524950A (en)
KR (1) KR100500775B1 (en)
CN (1) CN1126536C (en)
AT (1) ATE275943T1 (en)
AU (1) AU736052B2 (en)
BE (1) BE1011045A3 (en)
BR (1) BR9808239A (en)
CA (1) CA2283133C (en)
DE (1) DE69826290T2 (en)
ES (1) ES2229483T3 (en)
HK (1) HK1026152A1 (en)
ID (1) ID22980A (en)
IL (1) IL131292A (en)
NZ (1) NZ337345A (en)
PL (1) PL190735B1 (en)
RO (1) RO120602B1 (en)
RU (1) RU2179017C2 (en)
WO (1) WO1998041194A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
US20050171119A1 (en) * 2002-01-09 2005-08-04 Ucb, S.A. Pharmaceutical formulations with modified release

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1050306A (en) * 1996-07-31 1998-02-20 Toyota Autom Loom Works Ltd Manufacture of hydrogen storage alloy electrode
BE1011045A3 (en) * 1997-03-14 1999-04-06 Ucb Sa Pharmaceutical composition for controlled release of active substances.
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
EP1117384A1 (en) * 1998-10-01 2001-07-25 Elan Pharma International Limited Controlled release nanoparticulate compositions
JP2001107258A (en) * 1999-10-06 2001-04-17 Hitachi Ltd Electroless copper plating method and plating apparatus and multilayer wiring board
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR20080015955A (en) * 1999-10-29 2008-02-20 유로-셀티크 소시에떼 아노뉨 Sustained Release Hydrocodone Formulations
EP1118321A1 (en) * 2000-01-14 2001-07-25 Ucb, S.A. Solid pharmaceutical compositions for the controlled delivery of active substances
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
WO2002036099A1 (en) 2000-10-30 2002-05-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
KR20090029314A (en) * 2001-06-28 2009-03-20 유씨비 파쉼 소시에떼아노님 Tablets containing cetirizine and pseudoephedrine
EE05357B1 (en) * 2001-06-28 2010-12-15 Ucb, Farchim, S.A. A tablet containing at least two distinct segments and its use
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
IL164106A0 (en) * 2002-04-04 2005-12-18 Pfizer Prod Inc Palatable chewable tablet
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
DE60322577D1 (en) * 2002-12-06 2008-09-11 Ucb Farchim Sa TABLET CONTAINING EFLECTIRIZIN AND PSEUDOEPHEDRIN
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050281875A1 (en) * 2003-12-17 2005-12-22 Sovereign Pharmaceuticals, Ltd. Promethazine containing dosage form
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20060029664A1 (en) * 2004-08-04 2006-02-09 Sovereign Pharmaceuticals, Ltd. Dosage form containing carbetapentane and another drug
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20050232987A1 (en) * 2004-03-12 2005-10-20 Viswanathan Srinivasan Dosage form containing a morphine derivative and another drug
US20050232986A1 (en) * 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
US7897172B2 (en) * 2004-05-18 2011-03-01 L. Perrigo Company Tablets exhibiting reduced drug release variability
US9308164B2 (en) * 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
US9592197B2 (en) * 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
WO2006022996A2 (en) * 2004-08-04 2006-03-02 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US7529255B2 (en) * 2005-04-21 2009-05-05 Microsoft Corporation Peer-to-peer multicasting using multiple transport protocols
KR20080030546A (en) * 2005-07-26 2008-04-04 유씨비 파마, 에스.에이. Pharmaceutical composition comprising levetiracetam and method for preparing the same
US7829120B2 (en) 2005-09-09 2010-11-09 Labopharm Inc. Trazodone composition for once a day administration
AU2007205866B2 (en) * 2006-01-21 2012-11-29 Abbott Gmbh & Co. Kg Dosage form and method for the delivery of drugs of abuse
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
KR100753480B1 (en) * 2006-01-27 2007-08-31 씨제이 주식회사 Zaltoprofen-containing sustained-release tablets and preparation method thereof
US20070253927A1 (en) * 2006-04-13 2007-11-01 Gwenaelle Jegou Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
WO2007141743A2 (en) * 2006-06-06 2007-12-13 Ranbaxy Laboratories Limited A tablet dosage form comprising cetirizine and pseudoephedrine
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
EP2029116A4 (en) * 2006-06-19 2012-07-04 Accu Break Technologies Inc Segmented pharmaceutical dosage forms
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8045677B2 (en) 2006-09-25 2011-10-25 Koninklijke Philips Electronics N V Eindhoven Shifting an object for complete trajectories in rotational X-ray imaging
EP2813144A1 (en) * 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgesic compositions comprising an antihistamine
MX2009005339A (en) * 2006-11-21 2009-06-01 Mcneil Ppc Inc Modified release analgesic suspensions.
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
CN101827590A (en) * 2007-10-16 2010-09-08 莱博法姆公司 Be used for continuing to discharge the bilayer composition of acetaminophen and tramadol
RU2476240C2 (en) * 2007-11-21 2013-02-27 Дзе Проктер Энд Гэмбл Компани Preparations effective for treating cough
WO2009076764A1 (en) 2007-12-17 2009-06-25 Labopharm Inc. Misuse preventative, controlled release formulation
ES2620672T3 (en) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Double layer tablets comprising oxycodone and promethazine
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
WO2010069050A1 (en) 2008-12-16 2010-06-24 Labopharm Inc. Misuse preventative, controlled release formulation
BRPI0923836A2 (en) 2008-12-31 2015-07-21 Upsher Smith Lab Inc Opioid-containing oral pharmaceutical compositions and methods
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
CA2773521C (en) 2009-09-17 2017-01-24 Upsher-Smith Laboratories, Inc. A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
WO2011143120A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholres i stant metoprolol - containing extended - release oral dosage forms
CN102302497A (en) * 2011-05-18 2012-01-04 天圣制药集团股份有限公司 Preparation for treating allergic rhinitis and preparation method thereof
RU2625550C2 (en) 2013-02-13 2017-07-14 Дзе Проктер Энд Гэмбл Компани Anis-aromatised drug
KR102070076B1 (en) * 2013-05-03 2020-01-29 주식회사 제닉 Film comprising carbonic acid-containing particles
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
CA2941829C (en) * 2014-03-11 2021-11-02 Redhill Biopharma Ltd Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
RU2687715C1 (en) * 2018-05-07 2019-05-15 Федеральное государственное бюджетное учреждение науки Институт горного дела Дальневосточного отделения Российской академии наук Method of combined development of gold deposits
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
KR102073185B1 (en) * 2019-07-16 2020-02-04 (주)위바이오트리 Metal hydroxide complex comprising modified layered hydroxide comprising active component and method for preparing the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US477033A (en) * 1892-06-14 Bicycle
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
DE3681348D1 (en) 1985-06-11 1991-10-17 Teijin Ltd ORAL DRUG PREPARATION WITH RETARDIVE EFFECT.
DE3524572A1 (en) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K SOLID PHARMACEUTICAL FORMS FOR PERORAL USE CONTAINING 9-DEOXO-11-DEOXY-9,11- (IMINO (2- (2-METHOXYETHOXY) ETHYLIDEN) -OXY) - (9S) -ERYTHROMYCIN AND METHOD FOR THE PRODUCTION THEREOF
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
JPS6396126A (en) * 1986-10-13 1988-04-27 Taisho Pharmaceut Co Ltd stabilizing composition
IT1201136B (en) * 1987-01-13 1989-01-27 Resa Farma TABLET FOR PHARMACEUTICAL USE SUITABLE FOR THE RELEASE OF SUBSTANCES OF ACTIVE SUBSTANCES
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
IE60383B1 (en) * 1988-05-27 1994-07-13 Elan Corp Plc Controlled release pharmaceutical formulation
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
MX9300110A (en) * 1992-01-13 1994-07-29 Gerhard Gergely PHARMACEUTICAL PREPARATION IN THE FORM OF AN EFFERVESCENCE OR DISINTEGRATION TABLET OR OF AN INSTANT-TYPE GRANULATE AND PROCEDURE FOR ITS PREPARATION.
IT1255522B (en) * 1992-09-24 1995-11-09 Ubaldo Conte COMPRESSED FOR THERAPEUTIC USE SUITABLE FOR SELLING ONE OR MORE ACTIVE SUBSTANCES WITH DIFFERENT SPEEDS
US5411748A (en) * 1992-10-22 1995-05-02 Song Moon K Prostate extract supplemented with zinc
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
AU697456B2 (en) * 1994-06-15 1998-10-08 Dumex-Alpharma A/S Pellets
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
CA2277220A1 (en) * 1997-01-10 1998-07-16 Abbott Laboratories Tablet for the controlled release of active agents
BE1011045A3 (en) * 1997-03-14 1999-04-06 Ucb Sa Pharmaceutical composition for controlled release of active substances.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171119A1 (en) * 2002-01-09 2005-08-04 Ucb, S.A. Pharmaceutical formulations with modified release
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use

Also Published As

Publication number Publication date
CN1126536C (en) 2003-11-05
JP2001524950A (en) 2001-12-04
US6699502B1 (en) 2004-03-02
RU2179017C2 (en) 2002-02-10
US7083807B2 (en) 2006-08-01
RO120602B1 (en) 2006-05-30
HK1026152A1 (en) 2000-12-08
AU736052B2 (en) 2001-07-26
CN1250371A (en) 2000-04-12
US20040086563A1 (en) 2004-05-06
CA2283133A1 (en) 1998-09-24
EP1007005A1 (en) 2000-06-14
BE1011045A3 (en) 1999-04-06
AU6387398A (en) 1998-10-12
PL335832A1 (en) 2000-05-22
PL190735B1 (en) 2005-12-30
KR20000076269A (en) 2000-12-26
BR9808239A (en) 2000-05-16
NZ337345A (en) 2000-04-28
IL131292A (en) 2004-07-25
ID22980A (en) 1999-12-23
CA2283133C (en) 2006-07-25
KR100500775B1 (en) 2005-07-12
ES2229483T3 (en) 2005-04-16
IL131292A0 (en) 2001-01-28
DE69826290D1 (en) 2004-10-21
DE69826290T2 (en) 2005-02-17
EP1007005B1 (en) 2004-09-15
ATE275943T1 (en) 2004-10-15
WO1998041194A1 (en) 1998-09-24

Similar Documents

Publication Publication Date Title
US6699502B1 (en) Pharmaceutical compositions for controlled release of active substances
US6861072B1 (en) Pharmaceutical composition with gastric residence and controlled release
JP5572616B2 (en) Orally dispersible multilayer tablets
US7569612B1 (en) Methods of use of fenofibric acid
KR101125268B1 (en) Orally-dispersible multilaer tablet
US20100278912A1 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US20090263478A1 (en) Carvedilol forms, compositions, and methods of preparation thereof
US20060246003A1 (en) Composition containing anti-dementia drug
US9393204B2 (en) Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US20150283091A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
US9820936B2 (en) Oral controlled release pharmaceutical compositions of Bepotastine
CZ298851B6 (en) Controlled-release tablet for oral administration of active substances
US20050244498A1 (en) Modified-release compositions of at least one form of venlafaxine
US20090202633A1 (en) Extended release formulations of guaifenesin
US20050171119A1 (en) Pharmaceutical formulations with modified release
KR20040005257A (en) Pharmaceutical compositions of Controlled release
MXPA99008148A (en) Pharmaceutical compositions for controlled release of active substances
SA98190484B1 (en) Pharmaceutical formulations for controlled release of active substances

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载